Huntington's disease: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• HTT 2
• NRF2 0
• BDNF 1
• STING 0
• AKT 0
• AMPK 1
• NLRP3 0
• SIRT1 0
• PI3K 0
• HMGB1 0
• PPAR 0
• C9orf72 0
• HDAC 0
• HIF-1 0
• HSP90 0
• NMDA 0
• TDP-43 0
• TLR4 0
• APP 0
• BCL-2 0
• CD30 0
• CFTR 1
• CTNNB1 0
• DMD 1
• ERK 0
• EZH2 0
• G6PD 0
• GLP-1 0
• GPX4 0
• IL-17 0
• JNK 0
• LRRK2 0
• MMP-9 0
• mTOR 0
• NF1 1
• PINK1 0
• PSEN1 0
• SMN1 1
• SOD1 0
• STAT3 0
• TP53 0
• YAP 0

22 of 22+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NINDS · K99

  Post translational modifications as a therapeutic target for Huntington's Disease

  University of California-Irvine· Irvine, United States· US$119,840 awarded in fiscal year 2026· until Aug 2028

• NIH NIA · R43

  Non-Invasive Diagnostic Assays for Neurodegenerative Diseases

  Sonas Biotechnologies Inc· Eugene, United States· US$499,745 awarded in fiscal year 2026· until Sept 2027

• NIH NINDS · DP2

  RNA-Templated DNA Repair as a Genome Maintenance Pathway in Neurons

  University of Colorado Denver· Aurora, United States· US$741,000 awarded in fiscal year 2026· until Jun 2031

• NIH NINDS · R56

  The Mechanism of Trinucleotide Repeat Disease Expansions

  Ohio State University· Columbus, United States· US$551,250 awarded in fiscal year 2026· until Aug 2027

• NIH NINDS · RM1

  DECIPHERING THE MOLECULAR BASIS OF SOMATIC GAA-REPEAT DYNAMICS IN SCA27B

  University of Miami School of Medicine· Coral Gables, United States· US$1,819,495 awarded in fiscal year 2026· until Jul 2031

• European Commission (Horizon Europe) · HORIZON-ERC

  Ubiquitin Signaling as a Key Regulator of Aging and Neurodegeneration (UbiAge)

  Johann Wolfgang Goethe-Universitaet Frankfurt Am Main· Frankfurt Am Main, Germany· EU contribution €1,489,985· until Mar 2032

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Curation, Integration, Modelling and Rational Design of Small Molecule Amyloid Inhibitors (AmyStoppers)

  Vilniaus Universitetas· Vilnius, Lithuania· EU contribution €196,976· until Mar 2029

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  HDFACT82: Functional characterisation of CCDC82 and its interaction with FACT in Huntington’s disease

  Agencia Estatal Consejo Superior de Investigaciones Cientificas· Madrid, Spain· EU contribution €194,075· until Feb 2029

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Treatment of depression and cognitive decline in Huntington's Disease: Cannabinoids as a Dual Therapeutic Approach (TACHD)

  Fundacio de Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi I Sunyer· Barcelona, Spain· EU contribution €194,075· until Sept 2028

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Astrocyte Exosome Cargo as a Mediator of Non-Cell-Autonomous Neurodegeneration in Huntington’s Disease (AstroExo-HD)

  Siec Badawcza Lukasiewicz - Port Polski Osrodek Rozwoju Technologii· Wrocaw, Poland· EU contribution €179,006· until May 2028

10 of 278 running projects, newest first. Listed amounts together: US$148.6m + €30.4m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Withdrawn

  Safety and Tolerability Study With VY-HTT01, in Adults With Early Manifesting Huntington's Disease

  NCT04885114· Voyager Therapeutics· Updated 16 Aug 2021

  “We have discontinued our 1st generation HD program with the VYTAL Study \& have initiated a 2nd generation program using a novel, proprietary AAV capsid that may enable intravenous administration \& achieve widespread distribution to affected tissue.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 4
• Organoids 4
• CRISPR-Cas Systems 11
• Gene Expression Profiling 13
• Sequence Analysis, RNA 2
• Whole Genome Sequencing 1
• Proteomics 10
• Metabolomics 1
• Mass Spectrometry 1
• Immunohistochemistry 2
• Liquid Biopsy 1
• Positron-Emission Tomography 10
• Magnetic Resonance Imaging 28
• Machine Learning 11
• Deep Learning 4
• Cohort Studies 8
• Genome-Wide Association Study 6

• Melatonin-mediated β-catenin activation protects neuron cells against prion protein-induced neurotoxicity.

  J Pineal Res, Oct 2014

• Protective effects of ginseng saponins on 3-nitropropionic acid-induced striatal degeneration in rats.

  Neuropharmacology, Apr 2005

See which targets of this disease your abstract mentions, and go to the people working on them.